Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Clinical Outcomes2 items
Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience
Read →
Background: Short bowel syndrome-associated intestinal failure (SBS-IF) requires long-term parenteral nutrition (PN), increasing the risk of complications such as central line associated bloodstream infections, sepsis and liver disease. Ted
article · Nov 2026
Teduglutide's Impact on Short Bowel Syndrome: Reducing TPN Needs and Promoting Rehabilitation w/ Dr. Paul Wales
Watch →
Dr. Paul Wales discusses the therapeutic benefits of teduglutide for patients with Short Bowel Syndrome (SBS). He explains how this altered hormone analog addresses the short half-life of the native hormone, leading to a significant 40% red
video0:32 · Oct 2026
Cost-Utility Analysis1 item
Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome
Read →
Background & Aims: A growing proportion of children with short bowel syndrome (SBS) remain dependent on long-term parenteral nutrition (PN). Teduglutide offers the potential for more children to decrease PN support and achieve enteral auton
article · Nov 2026
Association between 4%-tetrasodium EDTA and sepsis in neonatal piglets: A retrospective cohort study.
Read →
Central line-associated bloodstream infections are a major concern for children with intestinal failure and in animal research using parenteral nutrition (PN). In neonatal piglets receiving PN, we compared sepsis, line occlusions, line repl
article · Nov 2026
Cost-utility analysis of 4% tetrasodium ethylenediaminetetraacetic acid, taurolidine, and heparin lock to prevent central line-associated bloodstream infections in children with intestinal failure.
Read →
Central line-associated bloodstream infections (CLABSI) are a serious complication in children with intestinal failure. This study assessed the incremental costs of 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) compared with tauroli
article · Nov 2026
Summaries and takeaways+ Show
Summary of this collection+ Show
Key points+ Show
Featured picks for families are being prepared — the summaries above are written for you.
Takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Expert statements from the recordings in this collection.
What's new+ Show